These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12486229)

  • 21. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.
    Southwell AL; Khoshnan A; Dunn DE; Bugg CW; Lo DC; Patterson PH
    J Neurosci; 2008 Sep; 28(36):9013-20. PubMed ID: 18768695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
    Wang H; Lim PJ; Karbowski M; Monteiro MJ
    Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis implicates the amyloid fibril as the toxic entity in Huntington's disease.
    Drombosky KW; Rode S; Kodali R; Jacob TC; Palladino MJ; Wetzel R
    Neurobiol Dis; 2018 Dec; 120():126-138. PubMed ID: 30171891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity of copper and zinc alone and in combination in Caenorhabditis elegans model of Huntington's disease and protective effects of rutin.
    Cordeiro LM; Soares MV; da Silva AF; Dos Santos LV; de Souza LI; da Silveira TL; Baptista FBO; de Oliveira GV; Pappis C; Dressler VL; Arantes LP; Zheng F; Soares FAA
    Neurotoxicology; 2023 Jul; 97():120-132. PubMed ID: 37302585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421.
    Pardo R; Colin E; Régulier E; Aebischer P; Déglon N; Humbert S; Saudou F
    J Neurosci; 2006 Feb; 26(5):1635-45. PubMed ID: 16452687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The selective vulnerability of nerve cells in Huntington's disease.
    Sieradzan KA; Mann DM
    Neuropathol Appl Neurobiol; 2001 Feb; 27(1):1-21. PubMed ID: 11298997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.
    Steffan JS; Thompson LM
    Expert Opin Ther Targets; 2003 Apr; 7(2):201-13. PubMed ID: 12667098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping of the epitope of monoclonal antibody 2B4 to the proline-rich region of human Huntingtin, a region critical for aggregation and toxicity.
    Dehay B; Weber C; Trottier Y; Bertolotti A
    Biotechnol J; 2007 May; 2(5):559-64. PubMed ID: 17373643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PolyQ-independent toxicity associated with novel translational products from CAG repeat expansions.
    Rudich P; Watkins S; Lamitina T
    PLoS One; 2020; 15(4):e0227464. PubMed ID: 32240172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-to-cell Transmission of Polyglutamine Aggregates in
    Kim DK; Cho KW; Ahn WJ; Perez-Acuña D; Jeong H; Lee HJ; Lee SJ
    Exp Neurobiol; 2017 Dec; 26(6):321-328. PubMed ID: 29302199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meclizine is neuroprotective in models of Huntington's disease.
    Gohil VM; Offner N; Walker JA; Sheth SA; Fossale E; Gusella JF; MacDonald ME; Neri C; Mootha VK
    Hum Mol Genet; 2011 Jan; 20(2):294-300. PubMed ID: 20977989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new Caenorhabditis elegans model of human huntingtin 513 aggregation and toxicity in body wall muscles.
    Lee AL; Ung HM; Sands LP; Kikis EA
    PLoS One; 2017; 12(3):e0173644. PubMed ID: 28282438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic activation of AMPK prevents from polyglutamine-induced toxicity in Caenorhabditis elegans.
    Gómez-Escribano AP; Bono-Yagüe J; García-Gimeno MA; Sequedo MD; Hervás D; Fornés-Ferrer V; Torres-Sánchez SC; Millán JM; Sanz P; Vázquez-Manrique RP
    Pharmacol Res; 2020 Nov; 161():105105. PubMed ID: 32739430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-PolyQ Antibodies Recognize a Short PolyQ Stretch in Both Normal and Mutant Huntingtin Exon 1.
    Owens GE; New DM; West AP; Bjorkman PJ
    J Mol Biol; 2015 Jul; 427(15):2507-2519. PubMed ID: 26047735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart.
    Melkani GC; Trujillo AS; Ramos R; Bodmer R; Bernstein SI; Ocorr K
    PLoS Genet; 2013; 9(12):e1004024. PubMed ID: 24367279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ.
    Li X; Hernandez I; Koyuncu S; Kis B; Häggblad M; Lidemalm L; Abbas AA; Bendegúz S; Göblös A; Brautigam L; Lucas JJ; Carreras-Puigvert J; Hühn D; Pircs K; Vilchez D; Fernandez-Capetillo O
    EBioMedicine; 2024 May; 103():105124. PubMed ID: 38701619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Huntington's disease: intracellular signaling pathways and neuronal death].
    Humbert S; Saudou F
    J Soc Biol; 2005; 199(3):247-51. PubMed ID: 16471265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
    Jana NR; Zemskov EA; Wang Gh ; Nukina N
    Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation and Characterization of Knock-in Mouse Models Expressing Versions of Huntingtin with Either an N17 or a Combined PolyQ and Proline-Rich Region Deletion.
    André EA; Braatz EM; Liu JP; Zeitlin SO
    J Huntingtons Dis; 2017; 6(1):47-62. PubMed ID: 28211815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans.
    Khan LA; Bauer PO; Miyazaki H; Lindenberg KS; Landwehrmeyer BG; Nukina N
    J Neurochem; 2006 Jul; 98(2):576-87. PubMed ID: 16805848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.